Commercial__O Impact__O Of__O New__O Business__O Creation__O With__O Established__O Viability:__O Background:__O The__O invention__O of__O DRAQ5&#8482;__O led__O to__O the__O creation__O in__O 2001__O of__O BioStatus__B-ORG Ltd__I-ORG (by__O Smith,__B-PER Patterson__I-PER and__O CEO__O Stefan__B-PER Ogrodzinski;__I-PER http://www.biostatus.com/aboutus.asp)__O to__O co-develop__O the__O dye__O technology,__O gain__O world-wide__O patent__O protection__O and__O develop__O a__O route__O for__O sustainable__O commercial__O impact.__O
A__O significant__O outcome__O was__O the__O creation__O of__O a__O new__O market__O for__O far-red__O molecular__O probes__O (primary__O and__O commercially-sensitive__O corroboration__O information__O from__O BioStatus__B-ORG Ltd__I-ORG CEO;__O Factual__O Statement)5.1,5.2.__O
Between__O 2002__O and__O 2008,__O BioStatus__B-ORG Ltd__I-ORG engaged__O academic__O opinion__O leaders__O and__O commercial__O organisations__O with__O a__O focus__O on__O flow__O cytometry__O -__O winning__O two__O New__B-ORG Technologies__I-ORG Initiative__I-ORG Awards__I-ORG in__O 2005__O and__O funding__O research__O at__O 4__O UK__B-LOC universities__O (Cardiff,__B-ORG Swansea,__I-ORG Nottingham__I-ORG and__O Bradford).__B-LOC
By__O 2009__O BioStatus__B-ORG Ltd__I-ORG had__O secured__O granted__O DRAQ__B-ORG patents5.3.__O
Biostatus__B-ORG Ltd__I-ORG remains__O privately__O owned__O and__O in__O 2009__O moved__O its__O direct__O sales__O and__O product__O development__O operations__O into__O its__O own__O 2,500__O sq__O ft__O office__O &amp;__B-MISC laboratory__O facility__O in__O Shepshed,__B-LOC Leicestershire5.1.__I-LOC
New__O product__O commercialized__O with__O revenue__O generation:__O In__O the__O impact__O period,__O DRAQ5&#8482;__B-ORG alone__O has__O an__O accumulated__O earnings__O of__O $3.2m,__O &gt;95%__B-ORG arising__O from__O export__O income,__O returning__O royalties__O of__O &gt;$180K5.1,5.2__B-ORG with__O a__O conservative__O estimate__O of__O ~5__O million__O sample__O assays__O performed__O to-date.__O
New__O linked__O start-ups__O funded__O by__O revenue__O from__O the__O core__O dye__O technology:__O In__O 2008__O Biostatus__B-ORG Ltd__I-ORG created__O Biosuspensions__B-ORG Ltd__I-ORG (www.biosuspensions.com__O Register__B-ORG No.06780280)__O to__O progress__O its__O new__O drug__O and__O probe__O delivery__O technology__O and__O in__O 2009__O created__O the__O award-winning__O Oncotherics__B-ORG Ltd__I-ORG (www.oncotherics.com;__O Register__B-ORG No.06940617)__O to__O progress__O a__O new__O anticancer__O drug__O based__O on__O its__O accumulated__O company__O expertise__O in__O molecular__O probe__O chemistry.__O
Global__O reach__O of__O the__O innovation:__O To__O extend__O commercial__O global__O reach,__O from__O 2008__O BioStatus__B-ORG established__O a__O widening__O network__O of__O key__O distributors__O including:__O ThermoFisher__B-ORG (2009-),__O e-Bio__B-MISC (now__O Affymetrix;__B-ORG 2009-)__O and__O AbCam__B-ORG (2010-).__O
By__O 2013,__O the__O reach__O of__O the__O technology__O to__O its__O research__O constituency__O was__O evidenced__O by__O its__O incorporation__O into__O research__O practice__O world-wide__O in__O over__O 500__O academic__O centres__O (source:__O client__O management__O database__O Biostatus__B-PER Ltd)5.1,5.2.__I-PER
By__O March__O 2013__O the__O widening__O significance__O and__O intensity__O of__O the__O influence__O of__O DRAQ5&#8482;__B-ORG was__O evidenced__O by__O its__O application__O featuring__O in__O 158__O peer-reviewed__O articles__O (101__O post-2008;__O source:__O SCOPUS)__B-ORG and__O a__O wider__O referencing__O of__O the__O use__O of__O DRAQ5&#8482;__O as__O a__O standard__O reagent__O in__O 3,060__O text__O articles__O (2,340__O post-2008;__O source:__O Google__B-PER Scholar).__I-PER
More__O recently,__O by__O October__O 2013__O SCOPUS__B-ORG reported__O 925__O Journal__B-ORG references__O for__O DRAQ5&#8482;__B-ORG and__O 338__O patent__O applications__O exploiting__O DRAQ__B-ORG technology__O published__O world-wide.__O
Recognition__O of__O impact:__O Successful__O translation__O of__O research__O through__O to__O product__O impact__O was__O recognised__O by__O the__O award__O of__O the__O 2012__O Royal__B-ORG Society__I-ORG of__I-ORG Chemistry__I-ORG Teamwork__I-ORG in__O Innovation__B-ORG Award__I-ORG to__O Smith,__B-ORG Patterson,__I-ORG Errington__I-ORG and__I-ORG Biostatus__I-ORG Ltd,__I-ORG "For__I-ORG worldwide__O exploitation__O and__O impact__O of__O novel__O fluorescent__O molecular__O probes__O and__O cell__O detection__O technologies__O in__O drug__O discovery,__O clinical__O diagnostics__O &amp;__B-ORG the__O life__O sciences"__O 5.4.__O
Job__O creation:__O BioStatus__B-ORG Ltd__I-ORG is__O an__O ISO__B-ORG 9001__O company,__O currently__O employs__O 8__O people__O and__O supports__O employment__O indirectly__O though__O contracted__O activities__O for__O legal,__O synthesis__O and__O business__O support__O services5.1,5.2.__O
Impact__O On__O Business__O And__O New__B-LOC Medicines__I-LOC Discovery__I-LOC Sector__I-LOC Through__I-LOC Adoption__I-LOC Of__O A__O New__B-MISC Technology:__I-MISC Early__I-MISC partnerships__O with__O antibody__O suppliers__O (Cell__B-ORG Signalling__I-ORG Technologies__I-ORG Inc,__I-ORG USA;www.cellsignal.com),__I-ORG major__O instrument__O developers__O (Amnis__B-ORG Corporation;__I-ORG now__O EMD__B-ORG Millipore)__I-ORG and__O high-throughput__O assay__O developers__O (Norak__B-ORG Biosciences,__I-ORG USA)__I-ORG led__O to__O validation__O for__O multi-colour__O microscopy__O and__O imaging__O cytometry__O with__O product__O adoption__O by__O March__O 20085.1,5.2.__O
DRAQ5&#8482;__O (product__O overview__O video:__O http://www.biostatus.com/SearchResults.asp?Cat=1889)__O is__O now__O used__O extensively__O on__O discovery__O imaging__O platforms__O with__O beneficiaries__O being:__O GlaxoSmithKline,__B-MISC the__O world's__O leading__O pharmaceutical__O company__O (GSK__B-ORG ranks__O #1,__O in__O the__O 2012__O Access__O to__O Medicine__B-ORG Index),__I-ORG other__O major__O drug__O companies__O (Roche,__B-ORG Bayer__I-ORG Schering__I-ORG &amp;__I-ORG Takeda/Nycomed)__I-ORG and__O contract__O high-throughput__O screening__O organisations__O (eg__O Odyssey__O Thera)__O involved__O in__O new__O medicine__O development__O for__O pharmaceutical__O clients.__O
Here__O the__O commercial__O impact__O has__O been__O a__O simplification__O of__O cell__O identification__O routines__O in__O imaging-based__O screens,__O cost-reduction/well,__O verified__O compatibility__O with__O multiple__O green__O fluorescent__O protein__O reporter-based__O assays3.6__O and__O reduced__O attrition__O of__O naturally__O fluorescent__O drug__O candidates__O in__O screens5.1.__O
Impact__B-ORG On__I-ORG Health__I-ORG Through__I-ORG Delivering__I-ORG Improvements__O To__O The__O Analysis__I-LOC Of__I-LOC Cells__I-LOC New__I-LOC reagents__O for__O clinical__O diagnostics:__O DRAQ__O technology__O has__O had__O the__O impact__O of__O delivering__O improvements__O to__O the__O accuracy__O of__O diagnostic__O assays__O in__O a__O wide__O range__O of__O flow__O cytometry__O applications__O while__O providing__O previously__O unattainable__O information__O or__O cost-savings__O in__O work__O flows.__O
An__O early__O trial__O in__O 2004__O showed__O that__O DRAQ&#8482;__B-MISC technology__O was__O readily__O adoptable__O by__O regional__O flow__O cytometry__O clinical__O laboratory__O services__O employing__O cost-saving__O and__O automated__O cytometers5.5.__O
DRAQ5__O is__O a__O validated__O reagent__O in__O multiple__O applications,__O typical__O examples__O are:__O improved__O rare__O cell__O detection__O in__O clinical__O diagnosis5.6,__O 5.7,__O more__O accurate__O myeloid__O to__O erythroid__O precursors__O ratio__O determinations__O and__O a__O simplified__O workflow__O in__O bone__O marrow__O analysis__O for__O haemato-oncology5.8,__O and__O improved__O detection__O of__O nucleated__O erythroblasts5.9.__O
Evidence__O of__O widespread__O adoption__O in__O clinical__O assays:__O DRAQ5&#8482;__O is__O featured__O directly__O in__O 29__O independent__O medical__O publications__O (source:__O SCOPUS__B-ORG search__O &lt;__B-PER DRAQ5&gt;)__I-PER providing__O evidence__O of__O the__O role__O of__O DRAQ5&#8482;__O in__O improving__O different__O clinical__O assays__O as__O a__O generic__O probe__O but__O for__O multiple__O cell__O types__O -__O typical__O examples__O being:__O DRAQ5&#8482;__B-ORG permitting__O the__O optimization__O of__O multi-colour__O approaches__O for__O the__O clinical__O analysis__O of__O cancer__O cells,__O DRAQ5&#8482;__B-ORG increasing__O the__O speed__O of__O assays__O by__O allowing__O single-step__O processing__O of__O clinical__O samples__O such__O as__O bone__O marrow__O aspirates,__O DRAQ5&#8482;__B-MISC simplifying__O assays__O by__O allowing__O nucleated__O cells__O to__O be__O identified__O in__O blood__O and__O bone__O marrow__O samples.__O
Further__O DRAQ5&#8482;__O introduces__O a__O new__O cell__O descriptor__O to__O enhance__O accuracy__O of__O diagnosis__O in__O lymphoproliferative__O disorders__O and__O plasma__O cell__O neoplasias.__O
DRAQ5&#8482;__O enables__O for__O the__O first__O time__O the__O simple__O extraction__O of__O proliferation__O index__O of__O specific__O bone__O marrow__O cell__O compartments__O -__O an__O important__O feature__O linked__O to__O patient__O outcomes.__O
The__O core__O technology__O also__O encompasses__O new__O derivatives.__O
For__O example__O DRAQ7__O detects__O cell__O viability__O and__O is__O to__O be__O supplied__O in__O 2013__O as__O a__O validated__O probe5.10__O by__O Beckman__B-ORG Coulter__I-ORG Inc__I-ORG -__O a__O leading__O in__O vitro__O diagnostics__O flow__O cytometry__O company.__O
DRAQ7__O is__O being__O evaluated__O further__O for__O an__O improved__O version__O of__O the__O ISHAGE__B-MISC protocol__O for__O Paroxysmal__B-ORG Nocturnal__I-ORG Hemoglobinuria__I-ORG diagnostics__O and__O for__O the__O standardization__O of__O flow__O cytometry__O for__O myelodysplastic__O syndromes.__O
